에 대한 최신 뉴스 Boston Scientific (NYSE:BSX) 주식

BOSTON SCIENTIFIC CORP

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Stock-Whisper-Index-Logo-6-copy copy

Exclusives

Trading Ideas

MELI

SOFI

UBER

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 우버, 보스톤 사이언티픽, EMCOR, 메르카도 리브레 및 소파이

Wall-Street-ai7-1

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

Tesla's Sky-High Surge

News

Previews

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a market capitalization of $150.91 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 15 years ago, it would be worth $1,560.09 today based on a price of $102.03 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746116414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $118 to $125.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $125

Trial achieves positive results in the treatment of persistent atrial fibrillation
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ --&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE&#x2122; Pulsed Field Ablation (PFA) System&#x2A; and adjunctive use of the FARAPOINT&#x2122; PFA Catheter in patients with persistent atrial fibrillation (AF). &nbsp;Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4411722-1&amp;h=2061933693&amp;u=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2F10.1161%2FCIRCULATIONAHA.125.074485&amp;a=Circulation">Circulation</a>.
Persistent AF, which accounts for approximately 25%1 of all AF cases, is an abnormal, rapid heartbeat that lasts for at least seven days in a row and can lead to complications such as blood clots, stroke and heart failure. The second phase of the ADVANTAGE AF trial studied the FARAWAVE&#x2122; PFA Catheter for both pulmonary vein isolation (PVI) and posterior wall ablation (PWA) and the FARAPOINT PFA Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter (AFL), a type of heart rhythm disorder. All patients in the trial were continuously monitored after their procedure with the LUX-Dx&#x2122; Insertable Cardiac Monitor (ICM) System, which is designed to detect recurrence of cardiac arrhythmias and assess AF burden. Findings from the trial met all pre-specified safety and effectiveness endpoints and demonstrated:
<ul>
<li>73.4% freedom from AF, AFL and atrial tachycardia (AT), which exceeded the performance goal of 40% or higher.</li>
<li>A safety event rate of 2.4% and no reports of pulmonary vein stenosis, atrio-esophageal fistula or phrenic nerve palsy which met the performance goal of 12% or lower.</li>
<li>81.0% freedom from symptomatic documented AF recurrence, which is defined as arrhythmia, clinical intervention or use of escalated or new Class I/III anti-arrhythmic drugs.</li>
<li>71.6% of patients had virtually no atrial arrhythmia (AA) burden, in which data shows lower AA burden can be associated with fewer clinical interventions and improvements in quality of life and 52% of patients had no residual AA events after the blanking period.</li>
<li>96.4% of patients treated with the FARAPOINT PFA Catheter had no recurrence of AFL.</li>
</ul>
Boston Scientific anticipates U.S. Food and Drug Administration approval to expand the instructions for use labeling for the FARAPULSE PFA System to include persistent AF as well as European and U.S. regulatory approvals for the FARAPOINT PFA Catheter in the second half of 2025.
 &nbsp;

Boston Scientific Says Second Phase Of ADVANTAGE AF Clinical Trial Of FARAPULSE Pulsed Field Ablation System Meets Primary Safety And Efficacy Endpoints

Needham analyst Mike Matson maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $113 to $115.

Needham Maintains Buy on Boston Scientific, Raises Price Target to $115

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) posted better-than-expected earnings for the <a href="https://www.benzinga.com/quote/BSX/earnings">first quarter on Wednesday</a>.
The company reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion. The company earned an adjusted EPS of 75 cents, beating the consensus of 67 cents and exceeding the management guidance of 66-68 cents.
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer of Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term."
Boston Scientific said it sees net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10%-12%, respectively.
The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.
Boston Scientific shares gained 2.4% to trade at $101.24 on Thursday.
These analysts made changes to their price targets on Boston Scientific following earnings announcement.
<ul>
<li>Baird analyst David Rescott maintained Boston Scientific with an Outperform rating and raised the price target from $115 to $120.</li>
<li>Evercore ISI Group analyst Vijay Kumar maintained the stock with an Outperform rating and increased the price target from $110 to $112.</li>
<li>Truist Securities analyst Richard Newitter maintained Boston Scientific with a Buy rating and raised the price target from $113 to $117.</li>
<li>RBC Capital analyst Shagun Singh maintained Boston Scientific with an Outperform rating and raised the price target from $116 to $120.</li>
</ul>
Considering buying BSX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-1024x611.png" alt="" class="wp-image-887296" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

Markets

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $116 to $120.

RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $120

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $113 to $117.

Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $117

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $110 to $112.

Evercore ISI Group Maintains Outperform on Boston Scientific, Raises Price Target to $112

Baird analyst David Rescott maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $115 to $120.

Baird Maintains Outperform on Boston Scientific, Raises Price Target to $120

Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration h<a href="https://www.benzinga.com/markets">elped lift investor confidence.</a>
The administration eased market fears on two major fronts that have recently weighed heavily on sentiment. On the trade front, tensions with China appeared to thaw, with reports suggesting the White House is considering reducing tariffs on certain categories of goods.
U.S. Treasury Secretary Scott Bessent added fuel to the rally, stating U.S.-China tariffs are unsustainable and will likely need to be lowered to facilitate meaningful negotiations.
Meanwhile, President Donald Trump offered an abrupt shift in tone toward Federal Reserve Chair Jerome Powell, saying he has no intention to fire him, a remark that helped calm concerns over political interference in monetary policy.
By midday in New York, the S&amp;P 500 was up by nearly 2%, though it had earlier climbed even higher. The Nasdaq 100 outperformed with a 2.5% gain, driven by strength in Magnificent Seven stocks.
Trump's pivot on Powell pushed Treasury yields lower across the curve, with the 30-year yield falling five basis points to 4.83%, after briefly topping 4.90% the previous day.
On the macro front, flash Purchasing Managers&#8217; Index surveys revealed slowing growth momentum in the U.S. economy, as the services sector decelerated sharply following the impact <a href="https://www.benzinga.com/government/regulations/25/04/44952395/us-business-activity-growth-slows-in-april-as-services-suffer-tariff-shock-markets-rally-as-trade-war-cools">of recent tariff shocks.</a>
The U.S. dollar strengthened, while gold plunged 2.6%, heading for its worst session since November.
Oil prices dropped more than 2% following speculation that OPEC+ may announce a new output hike as early as next month.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $93,000.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,732.09</td>
<td>+455.68</td>
<td>2.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,926.45</td>
<td>+37.40</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,384.67</td>
<td>+96.91</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,724.87</td>
<td>+537.89</td>
<td>1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.9% to $537.35.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.4% to $397.79.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.7% to $456.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 2.1% to $191.47.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3.44%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 6.6% despite falling short on both earnings and revenue expectations, as CEO Elon Musk reassured investors by pledging to scale back his involvement with DOGE and refocus on the company.</li>
</ul>
Other stocks reacting to earnings report included: 
<ul>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): up 2.8%</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>): down 2.6%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): up 4.6%</li>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>): up 4.7%</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>): up 3%</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>): down 1.7%</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>): down 4.3%</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>): down 14.4%​</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): down 0.5%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>): up 2.6%</li>
<li>NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): up 1%</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 4.8%</li>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>): down 3.4%</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): up 5.7%</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): up 1.4%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): down 3.8%</li>
<li>TE Connectivity Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>): up 2.7%</li>
<li>Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>): up 9.9%</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>): up 0.8%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 1.3%</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>): up 7.2%</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): down 2.1%</li>
<li>Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>): down 2.4%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>): down 8.2%</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>): up 5.2%</li>
<li>Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>): down 1.7%</li>
<li>Otis Worldwide Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>): down 6%​</li>
</ul>
<ul>
<li>Stocks slated to report earnings after the bell include Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>), ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Resmed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Rollins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Tyler Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>), Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), and Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports">Goldman Sachs Backs &#8216;Copper Tariff Trade&#8217; If Trump Slaps 25% Duty On US Imports</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Federal Reserve

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

ISRG

LRCX

OTIS

STLD

Select Sector SPDR-Consumer Discretionary

Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the&nbsp;consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44944464/boston-scientific-announces-results-for-first-quarter-2025" rel="noreferrer noopener">estimate of $4.57 billion</a>.
Sales increased 20.9% on a reported basis, compared to the company&#8217;s guidance range of 17%-19%, and 22.2% on an operational basis, 18.2% on an organic basis, compared to the company&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43494194/boston-scientific-clocks-22-jump-in-q4-sales-on-strong-heart-devices-profit-and-guidance-exceeds-expectations" rel="noreferrer noopener">guidance range of 14%-16%</a>.
The company earned an adjusted EPS of 75 cents, beating <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of 67 cents</a> and exceeding the management&nbsp;guidance of 66-68 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
The company&#8217;s cardiovascular segment generated sales of $3.09 billion, rising 26.2% (27.6% operationally and 25.6% organically). Boston Scientific reported a 29.8% growth in cardiology products to $2.43 billion and 14.4% in peripheral interventions, with sales of $656 million.
MedSurg segment revenues of $1.58 billion increased by 11.7% (12.8% operationally and 25.6% organically). Urology led the way with a 23.5% increase with sales of $633 million. Neuromodulation sales increased 5.8% to $271 million, and Endoscopy sales increased 4.7% to $673 million.
&#8220;We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio,&#8221; said&nbsp;Mike Mahoney, chairman and chief executive officer of Boston Scientific. &#8220;We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term.&#8221;
CFO Transition: Boston Scientific on Wednesday announced that&nbsp;Dan Brennan, executive vice president and CFO, will retire after nearly 30 years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44944797/boston-scientific-chief-financial-officer-cfo-dan-brennan-to-retire-jon-monson-senior-vice-preside" rel="noreferrer noopener">early&nbsp;October 2025</a>.&nbsp;
Jon Monson, currently senior vice president, Investor Relations will succeed Brennan as executive vice president and CFO, effective&nbsp;June 30.
Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10%-12%, respectively.
The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.
The company estimates second quarter 2025 net sales growth of approximately 17.5%-19.5% on a reported basis and approximately 13%-15% on an organic basis, with adjusted EPS of 71-73 cents compared to consensus of 71 cents.
In March, &nbsp;Boston Scientific agreed to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44083966/boston-scientific-to-acquire-sonivie-for-400-million-expanding-hypertension-treatment-portfolio" rel="noreferrer noopener">Intravascular Ultrasound System</a>.
Boston Scientific currently holds an equity stake of approximately 10%. Therefore, the transaction consists of an upfront payment of approximately&nbsp;$360 million&nbsp;for the 90% and up to&nbsp;$180 million&nbsp;upon achievement of a regulatory milestone.
Price Action: BSX stock is up 6.12% at $100.87 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" target="_blank" rel="noreferrer noopener">Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence</a></li>
</ul>
Photo via Shutterstock

Guidance

Health Care

Movers

General

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition

Management

Boston Scientific Announced That Dan Brennan, Executive Vice President And Chief Financial Officer, Has Elected To Retire At The End Of June And Disclosed Jon Monson As His Replacement Effective June 30, 2025

WIIM

Boston Scientific shares are trading higher after the company reported better-than-expected Q1 financial results and raised its 2025 adjusted EPS guidance.

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is looking for Q2 Adj EPS of $0.71-$0.73 vs $0.71 analyst estimate..

Boston Scientific Sees Q2 Adj EPS $0.71-$0.73 vs $0.71 Est and estimates net sales growth for the second quarter of 2025 to be in a range of approximately 17.5 to 19.5 percent on a reported basis versus the prior year period

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is looking for Q2 GAAP EPS of $0.45-$0.47 vs $0.48 analyst estimate..

Boston Scientific Sees Q2 GAAP EPS $0.45-$0.47 vs $0.48 Est

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) raises FY2025 Adj EPS guidance from $2.80-$2.87 to $2.87-$2.94 vs $2.86 analyst estimate..

Boston Scientific Raises FY2025 Adj EPS Guidance from $2.80-$2.87 to $2.87-$2.94 vs $2.86 Est and estimate net sales growth for the full year 2025 to be approximately 15 to 17 percent versus the prior year period

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) affirms FY2025 GAAP EPS guidance from $1.86-$1.93 to $1.86-$1.93 vs $1.96 analyst estimate..

Boston Scientific Affirms FY2025 GAAP EPS Guidance of $1.86-$1.93 vs $1.96 Est

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.67 by 11.94 percent. This is a 33.93 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $4.66 billion which beat the analyst consensus estimate of $4.57 billion by 1.99 percent. This is a 20.93 percent increase over sales of $3.86 billion the same period last year.

Earnings Beats

Boston Scientific Q1 Adj. EPS $0.75 Beats $0.67 Estimate, Sales $4.66B Beat $4.57B Estimate

AMTB

ASGN

BANC

BPOP

BRKL

BWFG

CACI

CBAN

CHDN

COOP

CSLR

CVLG

New Oriental Education & Technology Group

EGBN

EPRT

GLPG

GSHD

HBNC

HCSG

IMAX

INBK

KALU

KREF

MTDR

OSBC

PLXS

PTEN

SEIC

Earnings Scheduled For April 23, 2025

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Boston Scientific to report an earnings per share (EPS) of $0.67.
Boston Scientific bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 0.05% increase in the share price the following trading session.
Here's a look at Boston Scientific's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.66</td>
<td>0.59</td>
<td>0.58</td>
<td>0.51</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.63</td>
<td>0.62</td>
<td>0.56</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745330596_0.png" alt="eps graph" />
<h3>Market Performance of Boston Scientific's Stock</h3>
Shares of Boston Scientific were trading at $93.58 as of April 21. Over the last 52-week period, shares are up 29.63%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Boston Scientific</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Boston Scientific.
Analysts have given Boston Scientific a total of 13 ratings, with the consensus rating being Buy. The average one-year price target is $118.54, indicating a potential 26.67% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Stryker, Intuitive Surgical and Medtronic, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Stryker, with an average 1-year price target of $437.0, suggesting a potential 366.98% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Intuitive Surgical, with an average 1-year price target of $662.75, suggesting a potential 608.22% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Medtronic, with an average 1-year price target of $97.6, suggesting a potential 4.3% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Stryker, Intuitive Surgical and Medtronic, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Scientific</td>
<td>Buy</td>
<td>22.44%</td>
<td>$3.10B</td>
<td>2.66%</td>
</tr>
<tr>
<td>Stryker</td>
<td>Buy</td>
<td>10.68%</td>
<td>$4.17B</td>
<td>2.68%</td>
</tr>
<tr>
<td>Intuitive Surgical</td>
<td>Outperform</td>
<td>25.16%</td>
<td>$1.64B</td>
<td>4.28%</td>
</tr>
<tr>
<td>Medtronic</td>
<td>Neutral</td>
<td>2.51%</td>
<td>$5.51B</td>
<td>2.64%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Boston Scientific ranks second in revenue growth among its peers. It ranks third in gross profit. It ranks last in return on equity.
<h3>Delving into Boston Scientific's Background</h3>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Boston Scientific: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 22.44% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.39% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Boston Scientific's ROE excels beyond industry benchmarks, reaching 2.66%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Boston Scientific's ROA excels beyond industry benchmarks, reaching 1.46%. This signifies efficient management of assets and strong financial health.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.51, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/BSX/earnings">To track all earnings releases for Boston Scientific visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Boston Scientific

Press Releases

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

Offerings

Boston Scientific announces pricing of €1.5 billion of senior notes

Boston Scientific announces completion of €1.5 billion offering of senior notes

Boston Scientific announces agreement to acquire SoniVie Ltd.

Boston Scientific announces conference call discussing first quarter 2025 results

Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

Boston Scientific announces results for first quarter 2025

Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints

Comments

Boston Scientific

뉴스

에 대한 최신 뉴스 Boston Scientific (NYSE:BSX) 주식

토요일, 1월 04, 2025

금요일, 10월 11, 2024

일요일, 7월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌